A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer

Robert W. Holloway, Premal Thaker, Alberto A. Mendivil, Sarfraz Ahmad, Ahmed N. Al-Niaimi, James Barter, Tiffany Beck, Setsuko K. Chambers, Robert L. Coleman, Sarah M. Crafton, Erin Crane, Eskander Ramez, Sharad Ghamande, Whitney Graybill, Thomas Herzog, Megan Dr Indermaur, Veena S. John, Lisa Landrum, Peter C. Lim, Joseph A. LucciMichael Mchale, Bradley J. Monk, Kathleen Nadine Moore, Robert Morris, David M. O'malley, Thomas J. Reid, Debra Richardson, Peter G. Rose, Jennifer M. Scalici, Dan Arin Silasi, Krishnansu Tewari, Edward W. Wang

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences